CA2954729C - Meningococcus vaccines - Google Patents

Meningococcus vaccines Download PDF

Info

Publication number
CA2954729C
CA2954729C CA2954729A CA2954729A CA2954729C CA 2954729 C CA2954729 C CA 2954729C CA 2954729 A CA2954729 A CA 2954729A CA 2954729 A CA2954729 A CA 2954729A CA 2954729 C CA2954729 C CA 2954729C
Authority
CA
Canada
Prior art keywords
seq
polypeptide
amino acid
acid sequence
fhbp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2954729A
Other languages
English (en)
French (fr)
Other versions
CA2954729A1 (en
Inventor
Alessia BIOLCHI
Brunella Brunelli
Marzia Monica Giuliani
Vega Masignani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CA2954729A1 publication Critical patent/CA2954729A1/en
Application granted granted Critical
Publication of CA2954729C publication Critical patent/CA2954729C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
CA2954729A 2014-07-17 2015-07-16 Meningococcus vaccines Active CA2954729C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14177563 2014-07-17
EP14177563.5 2014-07-17
PCT/EP2015/066229 WO2016008961A1 (en) 2014-07-17 2015-07-16 Meningococcus vaccines

Publications (2)

Publication Number Publication Date
CA2954729A1 CA2954729A1 (en) 2016-01-21
CA2954729C true CA2954729C (en) 2023-08-22

Family

ID=51178811

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2954729A Active CA2954729C (en) 2014-07-17 2015-07-16 Meningococcus vaccines

Country Status (15)

Country Link
US (3) US11707513B2 (enExample)
EP (1) EP3169358A1 (enExample)
JP (2) JP6687597B2 (enExample)
KR (2) KR20230012100A (enExample)
CN (2) CN106659776A (enExample)
AR (2) AR101225A1 (enExample)
AU (2) AU2015289193A1 (enExample)
BE (1) BE1022878B1 (enExample)
BR (1) BR112017000519A2 (enExample)
CA (1) CA2954729C (enExample)
EA (1) EA038940B1 (enExample)
IL (1) IL249823B (enExample)
MX (1) MX2017000775A (enExample)
SG (2) SG10201900041VA (enExample)
WO (1) WO2016008961A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106661092B (zh) 2014-02-28 2021-07-06 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
MX2017000776A (es) 2014-07-17 2017-05-04 Glaxosmithkline Biologicals Sa Polipeptidos fhbp meningococicos modificados.
AU2015289193A1 (en) 2014-07-17 2017-02-02 Glaxosmithkline Biologicals S.A. Meningococcus vaccines
US10975131B2 (en) * 2015-10-27 2021-04-13 University Of Massachusetts Factor H-Fc immunotheraphy
CN107961369B (zh) * 2017-03-22 2020-08-11 武汉博沃生物科技有限公司 多价脑膜炎球菌缀合疫苗及其制备方法
CN108939061A (zh) * 2018-08-03 2018-12-07 北京智飞绿竹生物制药有限公司 一种多组分b群脑膜炎球菌疫苗及其制备方法
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
US11014736B2 (en) 2019-04-18 2021-05-25 Altria Client Services Llc Sliding packs with flip top hinged lids
CN110804101A (zh) * 2019-11-08 2020-02-18 苏州微超生物科技有限公司 B群脑膜炎球菌相关融合蛋白、疫苗及其制备方法与应用
MX2022006299A (es) * 2019-11-25 2023-01-19 Univ Griffith Proteína inmunogénica contra una infección gonocócica.
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
CN119792505A (zh) * 2023-10-10 2025-04-11 康希诺生物股份公司 一种抗脑膜炎球菌的免疫组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
ES2588917T3 (es) * 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
EP2544714A1 (en) * 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
TR201802933T4 (tr) 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
GB201120634D0 (en) 2011-11-30 2012-01-11 Univ Sheffield Adjuvant polypeptide
ES2847923T3 (es) * 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
GB201215005D0 (en) 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
CN106661092B (zh) 2014-02-28 2021-07-06 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
EP2916512B1 (en) 2014-03-07 2016-08-24 Mitsubishi Electric R&D Centre Europe B.V. Method for classifying a TCP connection carrying HTTP traffic as a trusted or an untrusted TCP connection
MX2017000776A (es) 2014-07-17 2017-05-04 Glaxosmithkline Biologicals Sa Polipeptidos fhbp meningococicos modificados.
AU2015289193A1 (en) 2014-07-17 2017-02-02 Glaxosmithkline Biologicals S.A. Meningococcus vaccines
MX2021000081A (es) 2018-06-21 2021-03-25 Basf Se Derivados de difosfato de 3-fenil-benzofuran-2-ona como estabilizantes.

Also Published As

Publication number Publication date
CN106659776A (zh) 2017-05-10
IL249823B (en) 2022-07-01
JP6687597B2 (ja) 2020-04-22
US12485164B2 (en) 2025-12-02
AU2019201131B2 (en) 2020-08-27
BE1022878B1 (fr) 2016-09-30
JP2017522319A (ja) 2017-08-10
IL249823A0 (en) 2017-03-30
AR130778A2 (es) 2025-01-15
BR112017000519A2 (pt) 2017-11-21
BE1022878A1 (fr) 2016-09-30
KR20230012100A (ko) 2023-01-25
SG11201610946YA (en) 2017-01-27
CN113827712A (zh) 2021-12-24
JP2020117523A (ja) 2020-08-06
EP3169358A1 (en) 2017-05-24
WO2016008961A1 (en) 2016-01-21
EA201692554A1 (ru) 2017-07-31
EA038940B1 (ru) 2021-11-12
AU2015289193A1 (en) 2017-02-02
AR101225A1 (es) 2016-11-30
KR102626831B1 (ko) 2024-01-22
US11707513B2 (en) 2023-07-25
US20260097107A1 (en) 2026-04-09
AU2019201131C1 (en) 2021-03-18
JP7074793B2 (ja) 2022-05-24
MX2017000775A (es) 2017-05-04
CA2954729A1 (en) 2016-01-21
SG10201900041VA (en) 2019-02-27
KR20170029615A (ko) 2017-03-15
US20180214531A1 (en) 2018-08-02
AU2019201131A1 (en) 2019-03-07
US20230414736A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
US12485164B2 (en) Meningococcus vaccines
US11939357B2 (en) Modified meningococcal fHbp polypeptides
US12415838B2 (en) Modified meningococcal fHbp polypeptides
CN112566657B (zh) 修饰的脑膜炎球菌fHbp多肽
EA043165B1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200715

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250625

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250915